Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KY002
- Development stage
- Preclinical
- Lead developer
- KYDES Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
KY002 (also known as KY1102) is a topical non-steroidal anti-inflammatory drug (NSAID) developed by KYDES Pharmaceuticals. It is designed to address pain and inflammation of the joints while minimizing systemic toxicity. The product is being developed as a topical over-the-counter (OTC) medication for markets outside the United States. As of the current pipeline status, manufacturing and regulatory activities are underway to support its commercialization.
- Other names
- KY1102KY-1102KY 1102
02
Targets
COX
Beyond the preview
Go deeper on KY002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KY002.